Early Palliative Care – Health services research and implementation of sustainable changes

Organizational Data

DRKS-ID:
DRKS00006162
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2014-05-19
Last update in DRKS:
2024-01-23
Registration type:
Prospective

Acronym/abbreviation of the study

EVI

URL of the study

No Entry

Brief summary in lay language

At all five Comprehensive Cancer Centers throughout the federal state of Baden-Württemberg, Germany, patients with advanced metastatic cancer will routinely be offered palliative care as soon as possible after diagnosis, according to the most up-to-date international treatment standards. In each of the five participating Comprehensive Cancer Centers, an experienced palliative care physician will be hired for 18 months with a 50% position. During the preliminary phase of the study, the physician will be allowed time to establish the necessary structures for early palliative care within the clinic. In the main study phase, patients with metastatic cancer will routinely be offered a consultation with the palliative care physician within eight weeks of diagnosis. The main goal of the EVI project is to evaluate whether early palliative care can be implemented into the everyday clinical practice of Comprehensive Cancer Centers, and if so, what conditions are necessary for it to succeed. In addition, we are interested in (1) describing the type of support that patients would like from palliative care, (2) gaining information about the effect of palliative care on patients’ quality of life and healthcare costs, and (3) determining which factors could potentially ease or hinder the implementation of early palliative care, respectively. The long-term goal of this project is to create sustainable improvements in the care of patients with incurable, life-limiting cancer.

Brief summary in scientific language

The EVI project is a multi-center, prospective cohort study with a sequential control group design. The study is a project of the Palliative Care Center of Excellence (KOMPACT) in Baden-Württemberg, Germany, which was recently established to combine the expertise of five academic, specialist palliative care departments. The study is divided into two phases: preliminary phase (months 1-9) and main study phase (months 10-18). In each of all five participating academic Comprehensive Cancer Centers, an experienced palliative care physician will be hired for 18 months. During the preliminary phase, the physician will be allowed time to establish the necessary structures for early palliative care within the Comprehensive Cancer Center. In the main study phase, patients with metastatic cancer will be offered a consultation with the palliative care physician within eight weeks of diagnosis. After the initial consultation, follow-up consultations will be offered as needed. The study is built upon a converging, parallel mixed-method design. In the quantitative arm, patients will be surveyed in both the preliminary and main study phase at three points in time (baseline, 12 weeks, 24 weeks). Standardized questionnaires will be used to measure patients’ quality of life, symptom burden and mood. Using interviews with palliative care physicians, oncologists, department heads, patients and their caregivers, the qualitative arm of the study will explore (1) what factors encourage and hinder the early integration of palliative care into standard oncology care and (2) what support patients and their caregivers would like from palliative care.

Health condition or problem studied

ICD10:
C34 - Malignant neoplasm of bronchus and lung
ICD10:
C15 - Malignant neoplasm of oesophagus
ICD10:
C16 - Malignant neoplasm of stomach
ICD10:
C25 - Malignant neoplasm of pancreas
Free text:
center-specific tumor entities
Healthy volunteers:
No

Interventions, Observational Groups

Arm 1:
In the preliminary phase patients will be recruited to establish a reference group for comparison between the status quo and those in the main study phase who receive early palliative care.
Arm 2:
In the main study phase, patients with metastatic cancer will routinely be offered a consultation with the palliative care physician within eight weeks of diagnosis.

Endpoints

Primary outcome:
The main goal of the EVI project is to evaluate whether early palliative care can be implemented into the everyday clinical practice of Comprehensive Cancer Centers, and if so, what conditions are necessary for it to succeed. We will consider early palliative care to be feasible if 75% of all eligible patients are referred to a palliative care physician at their center at least once within eight weeks of the initial diagnosis. To judge the feasibility, we will rely on the internal records of the participating centers.
Secondary outcome:
The study is built upon a convergent parallel design. In the quantitative arm, patients will be surveyed in both the preliminary and main study phase at three points in time (baseline, 12 weeks, 24 weeks). Standardized questionnaires will be used to measure patients’ quality of life (EORTC QLQ-C30), symptom burden (POS - Palliative Outcome Scale) and mood (Hospital Anxiety and Depression Scale - HADS-D). Using interviews with palliative care physicians, oncologists, department heads, patients and their caregivers, the qualitative arm will explore (1) what factors encourage and hinder the early integration of palliative care into standard oncology care, (2) what support patients and their caregivers would like from palliative care, and (3) what effect palliative care has on the economic disease burden of patients and their families.

Study Design

Purpose:
Treatment
Allocation:
Non-randomized controlled study
Control:
  • Other
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Other
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Multicenter study
Recruitment location(s):
  • University medical center Heidelberg
  • University medical center Tübingen
  • University medical center Freiburg im Breisgau
  • University medical center Ulm

Recruitment period and number of participants

Planned study start date:
2014-08-01
Actual study start date:
2014-10-01
Planned study completion date:
No Entry
Actual Study Completion Date:
2017-07-21
Target Sample Size:
2000
Final Sample Size:
592

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
1. Initial diagnosis of a metastatic, incurable cancer (ICD 10 C 1‐80 plus ICD 10 C 78‐79) occurred within the last eight weeks, particularly: - non-small cell lung cancer (NSCLC) without epidermal growth factor (EFGR) mutations: met. NSCLC Stage IV – ICD C34.[01239] + metastasis code or C34.8 (multiple subdomains) + possibly M8012/3 (large cell carcinoma) - met. esophageal carcinoma Stage IV – ICD C15.[123459] + metastasis code or C15.8 (multiple subdomains) + possibly M8070/3 (squamous cell carcinoma) - met. stomach carcinoma Stage IV - ICD C16.[01234569] + metastasis code or C16.8 (multiple subdomains) + possibly M8145/3 (adenocarcinoma, diffuse) - non-endocrine pancreas carcinoma Stage IV - ICD C25.[012379] + metastasis code or C25.8 (multiple subdomains) + possibly M8971/3 (pancreas blastoma) - center-specific tumor entities 2. Age ≥ 18 years 3. Ability to understand written and verbal questions in German 4. Willingness to participate in the study 5. Informed consent

Exclusion Criteria

1. Other hemato-oncological disease (e.g. leukemia) 2. Dementia 3. Psychosis / delirium 4. Major depression

Addresses

Primary Sponsor

Address:
Klinik für Pallliativmedizin, Universitätsklinikum Freiburg
Prof. Gerhild Becker
Robert-Koch-Straße 3
79106 Freiburg
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Universitätsklinikum Freiburg, Klinik für Palliativmedizin
Katharina Seibel
Robert-Koch-Str. 3
79106 Freiburg
Germany
Telephone:
0761 270-33280
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-freiburg.de/palliativmedizin.html

Contact for Public Queries

Address:
Universitätsklinikum Freiburg, Klinik für Palliativmedizin
Katharina Seibel
Robert-Koch-Str. 3
79106 Freiburg
Germany
Telephone:
0761 270-33280
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-freiburg.de/palliativmedizin.html

Principal Investigator

Address:
Universitätsklinikum Freiburg, Klinik für Palliativmedizin
Katharina Seibel
Robert-Koch-Str. 3
79106 Freiburg
Germany
Telephone:
0761 270-33280
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-freiburg.de/palliativmedizin.html

Sources of Monetary or Material Support

Private sponsorship (foundations, study societies, etc.)

Address:
Robert-Bosch-Stiftung GmbH
Heidehofstr. 31
70184 Stuttgart
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
Engelberger Str. 21
79106 Freiburg
Germany
Telephone:
+49-761-27072600
Fax:
+49-761-27072630
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2014-04-14
Ethics committee number:
193/14
Vote of the Ethics Committee:
Approved
Date of the vote:
2014-04-25

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry